A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Altimmune, Inc.
ALT
$244M
Mkt Cap
$2.77
-2.46%
Altimmune, Inc. (ALT) has a 5-year average return on invested capital (ROIC) of -48.1%. This is below average and may indicate limited pricing power.
Altimmune, Inc. (ALT) has a market capitalization of $244M. It is classified as a small-cap stock.
Altimmune, Inc. (ALT) does not currently pay a regular dividend.
Altimmune, Inc. (ALT) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Altimmune, Inc. (ALT) generated $-68 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Altimmune, Inc. (ALT) has a debt-to-equity ratio of 0.16. This indicates a conservatively financed balance sheet.
Altimmune, Inc. (ALT) reported earnings per share (EPS) of $-1.00 in its most recent fiscal year.
Item 1. Business Altimmune, Inc. is a late clinical-stage biopharmaceutical company developing novel therapies for serious liver diseases. Our lead product candidate, pemvidutide (formerly known as ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), alcohol use disorder (“AUD”) and alcohol-associated liver disease (“ALD”). We may also pursue additional indications for pemvidutide that leverage its differentiated clinical profile. Except where the context indicates otherwise, references to “we,” “us,” “our,” “Altimmune”, or the “Company” refer to the company and its subsidiaries. We obtained pemvidutide as part of the acquisition Spitfire Pharma Inc., in July of 2019. Pemvidutide was designed as a MASH therapeutic based on the understanding that targeting both metabolic and liver-specific effects could lead to an improved and differentiated candidate.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - | - |
| Net Income | -88M | -88M | -95M | -88M | -85M | -97M |
| EPS | $-1.00 | $-1.00 | $-1.34 | $-1.66 | $-1.81 | $-2.35 |
| Free Cash Flow | -68M | -68M | -80M | -76M | -63M | -90M |
| ROIC | -34.4% | -46.0% | -59.9% | -46.1% | -43.4% | -45.3% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.16 | 0.16 | 0.01 | 0.00 | 0.03 | 0.02 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -94M | -94M | -103M | -96M | -88M | -97M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -39.2% | -50.6% | -59.9% | -46.6% | -44.1% | -45.7% |
| Shares Outstanding | 88M | 88M | 71M | 53M | 47M | 41M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | N/A | N/A | N/A | 11M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 9.3M | 5.1M | 7.2M | 18M | 18M | 18M | 50M | 75M | 71M | 66M | 82M | 66M | 66M |
| SG&A | 11M | 6.2M | 7.1M | 8.5M | 9.8M | 8.5M | 13M | 15M | 17M | 18M | 21M | 28M | 28M |
| EBIT | -10M | -3.4M | -11M | -52M | -43M | -21M | -55M | -97M | -88M | -96M | -103M | -94M | -94M |
| Op. Margin | N/A | N/A | N/A | -484.7% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -10.0M | -3.4M | -11M | N/A | -42M | -21M | -49M | -97M | -85M | -88M | -95M | -88M | -88M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 5K | 2.6M | 0 | 36M | 494K | 1.0M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||||||||
| ROIC | -78.6% | -20.7% | -30.4% | N/A | -90.3% | -43.0% | -35.7% | -45.3% | -43.4% | -46.1% | -59.9% | -46.0% | -34.4% |
| ROE | -77.7% | -19.7% | -30.4% | N/A | -96.9% | -44.7% | -36.1% | -45.7% | -44.1% | -46.6% | -59.9% | -50.6% | -39.2% |
| ROA | -50.9% | -16.4% | -39.3% | N/A | -72.1% | -38.6% | -32.8% | -41.9% | -39.8% | -42.4% | -54.3% | -42.0% | -31.5% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | -8.5M | -3.2M | -6.4M | -20M | -9.4M | -9.6M | -34M | -78M | -63M | -76M | -80M | -68M | -68M |
| Free Cash Flow | -8.6M | -3.3M | -6.5M | -20M | -10M | -9.6M | -35M | -90M | -63M | -76M | -80M | -68M | -68M |
| Owner Earnings | -10M | -4.0M | -7.4M | -22M | -10M | -11M | -37M | -84M | -71M | -87M | -94M | -84M | -84M |
| CapEx | 92K | 87K | 125K | 112K | 975K | 1K | 204K | 12M | 126K | 47K | 0 | 11K | 11K |
| Maint. CapEx | 150K | 142K | 63K | 84K | 219K | 387K | 429K | 551K | 493K | 477K | 238K | 112K | 112K |
| Growth CapEx | 0 | 0 | 62K | 29K | 757K | 0 | 0 | 12M | 0 | 0 | N/A | 0 | 0 |
| D&A | 150K | 142K | 63K | 84K | 219K | 387K | 429K | 551K | 493K | 477K | 238K | 112K | 112K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% | 0.0% |
| Stock-Based Comp | 1.7M | 613K | 965K | 1.4M | 773K | 1.3M | 2.6M | 5.5M | 8.1M | 11M | 14M | 16M | 16M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.1M | 1.1M |
| Balance Sheet | |||||||||||||
| Net Debt | -19M | -16M | -69M | -4.1M | -32M | -34M | -212M | -187M | -179M | -197M | -130M | -238M | -8.1M |
| Cash & Equiv. | 19M | 16M | 2.9M | 8.8M | 34M | 9.0M | 116M | 190M | 111M | 135M | 37M | 44M | 44M |
| Long-Term Debt | -1000K | -750K | 722K | 4.6M | 1.9M | 1.9M | 1.8M | 1.5M | 4.6M | N/A | N/A | 34M | 34M |
| Debt/Equity | -0.01 | -0.05 | 0.04 | 0.12 | 0.04 | 0.08 | 0.02 | 0.02 | 0.03 | 0.00 | 0.01 | 0.16 | 0.16 |
| Interest Coverage | -48.4 | -62.3 | -288.1 | -321.0 | -144.2 | -9565.5 | -5816.7 | -19382.8 | -10967.5 | -2740.8 | -11463.6 | -57.8 | -57.8 |
| Equity | 18M | 17M | 32M | 39M | 48M | 46M | 226M | 199M | 185M | 194M | 124M | 225M | 225M |
| Total Assets | 22M | 20M | 38M | 63M | 55M | 54M | 245M | 219M | 207M | 211M | 139M | 280M | 280M |
| Total Liabilities | 3.7M | 3.2M | 6.2M | 14M | 6.4M | 8.5M | 19M | 20M | 22M | 17M | 16M | 55M | 55M |
| Intangibles | N/A | N/A | 15M | 39M | 14M | 13M | 13M | 12M | 12M | 0 | 0 | N/A | N/A |
| Retained Earnings | -220M | -224M | -31M | -78M | -117M | -137M | -186M | -293M | -378M | -466M | -561M | -649M | -649M |
| Working Capital | 17M | 15M | -984K | 20M | 35M | 35M | 218M | 186M | 176M | 197M | 127M | 263M | 263M |
| Current Assets | 19M | 17M | 4.5M | 23M | 39M | 39M | 230M | 204M | 193M | 210M | 137M | 278M | 278M |
| Current Liabilities | 2.6M | 2.2M | 5.5M | 3.8M | 4.5M | 3.9M | 12M | 18M | 17M | 12M | 10M | 15M | 15M |
| Per Share Data | |||||||||||||
| EPS | -1.36 | -0.40 | -13.25 | -237.82 | -2.34 | -0.80 | -1.91 | -2.35 | -1.81 | -1.66 | -1.34 | -1.00 | -1.00 |
| Owner EPS | -1.40 | -0.46 | -8.54 | -71.46 | -0.57 | -0.43 | -1.45 | -2.04 | -1.52 | -1.63 | -1.33 | -0.95 | -0.95 |
| Book Value | 2.50 | 1.94 | 37.25 | 129.49 | 2.66 | 1.74 | 8.80 | 4.82 | 3.96 | 3.64 | 1.74 | 2.55 | 2.55 |
| Cash Flow/Share | -1.16 | -0.37 | -7.35 | -66.44 | -0.52 | -0.37 | -1.34 | -1.89 | -1.34 | -1.42 | -1.13 | -0.77 | -1.00 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 7.3M | 8.6M | 0.9M | 0.3M | 18.2M | 26.2M | 25.7M | 41.3M | 46.8M | 53.3M | 70.9M | 88.1M | 88.1M |
| Valuation | |||||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -2.8 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | 19.7 | 0.6 | 0.5 | 1.3 | 1.8 | 3.7 | 3.2 | 4.4 | N/A | 1.1 |
| Price/Sales | N/A | N/A | N/A | 96.5 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | N/A | N/A | -2.6% | -36.7% | -40.7% | -12.1% | -25.0% | -9.1% | -12.3% | -14.7% | N/A | -27.7% |
| Market Cap | 0 | N/A | N/A | 775M | 28M | 24M | 285M | 362M | 690M | 619M | 544M | 0 | 244M |
| Avg. Price | 0.00 | N/A | N/A | 77.07 | 21.20 | 2.42 | 9.89 | 13.14 | 9.86 | 5.93 | 7.99 | 0.00 | 2.77 |
| Year-End Price | 0.00 | N/A | N/A | 57.60 | 1.84 | 1.80 | 11.10 | 8.75 | 14.74 | 11.62 | 7.67 | 0.00 | 2.77 |
Altimmune, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Altimmune, Inc. (ALT) has a return on equity (ROE) of -50.6%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 16 years of financial data for Altimmune, Inc. (ALT), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Altimmune, Inc. (ALT) has a book value per share of $2.55, based on its most recent annual SEC filing.